- 著者
- 
             
             Ken YAMAGUCHI
             
             Kenichi URAKAMI
             
             Takeshi NAGASHIMA
             
             Yuji SHIMODA
             
             Shumpei OHNAMI
             
             Sumiko OHNAMI
             
             Keiichi OHSHIMA
             
             Tohru MOCHIZUKI
             
             Keiichi HATAKEYAMA
             
             Masakuni SERIZAWA
             
             Yasuto AKIYAMA
             
             Kouji MARUYAMA
             
             Hirohisa KATAGIRI
             
             Yuji ISHIDA
             
             Kaoru TAKAHASHI
             
             Seiichiro NISHIMURA
             
             Masanori TERASHIMA
             
             Taiichi KAWAMURA
             
             Yusuke KINUGASA
             
             Yushi YAMAKAWA
             
             Tetsuro ONITSUKA
             
             Yasuhisa OHDE
             
             Takashi SUGINO
             
             Ichiro ITO
             
             Hiroyuki MATSUBAYASHI
             
             Yasue HORIUCHI
             
             Maki MIZUGUCHI
             
             Mutsumi YAMAZAKI
             
             Kengo INOUE
             
             Kimiko WAKAMATSU
             
             Misato SUGIYAMA
             
             Katsuhiko UESAKA
             
             Masatoshi KUSUHARA
             
          
- 出版者
- バイオメディカルリサーチプレス
- 雑誌
- Biomedical Research (ISSN:03886107)
- 巻号頁・発行日
- vol.37, no.4, pp.259-264, 2016-08-01 (Released:2016-08-20)
- 参考文献数
- 25
- 被引用文献数
- 
             
             
             7
             
             
          
        
        Using whole exome sequencing data obtained from 1,685 Japanese cancer patients, we examined genetic variations of germline TP53 and found 10 types of non-synonymous single nucleotide variants. In the present study, we focused on 6 patients with germline D49H mutation located in the transactivation domain 2 of p53 protein, since the mutation seemed to be prevalent in cancer patients and to be pathogenic. According to the initial survey for family history of the proband with the germline TP53 D49H mutation, one osteosarcoma patient and his pedigree fulfill the criteria for Li-Fraumeni-like syndrome and the 2009 Chompret criteria for germline TP53 mutation screening. Since this patient possesses double germline mutations of TP53 D49H and A159D, further studies are required to evaluate contribution of the D49H mutation in this morbidity. The remaining 5 patients had family histories of cancer, but none fulfills the criteria either for the Li-Fraumeni/Li-Fraumeni-like syndromes or the 2009 Chompret criteria for germline TP53 mutation screening. It is possible to postulate that the germline TP53 D49H mutation is likely to be low-penetrant in some pedigrees. The present study also indicates that the survey for the germline TP53 mutation plays an important role in clinical practice as it will prevent mistaking cancer patients with unusual heredities for sporadic cases.